References of "Bruyère, Olivier"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailClinically meaningful effect of strontium ranelate on knee osteoarthritis symptoms
Bruyère, Olivier ULg; Bellamy, N; Brown, J et al

in Arthritis and Rheumatism (2012), 64(S10), 110

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailAntidepressant medications and osteoporosis
Rizzoli, R; Cooper, C; Reginster, Jean-Yves ULg et al

in BONE (2012), 51

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailEffect of collagen hydrolysate in articular pain: A 6-month randomized, double-blind, placebo controlled study
Bruyère, Olivier ULg; Zegels, Brigitte ULg; Leonori, Lorenzo et al

in Complementary Therapies in Medicine (2012), 20

Objective: Evaluation of the efficacy and safety of a food supplement made of collagen hydrolysate 1200 mg/day versus placebo during 6 months, in subjects with joint pain at the lower or upper limbs or at ... [more ▼]

Objective: Evaluation of the efficacy and safety of a food supplement made of collagen hydrolysate 1200 mg/day versus placebo during 6 months, in subjects with joint pain at the lower or upper limbs or at the lumbar spine. Design: Comparative double-blind randomized multicenter study in parallel groups. Setting: 200 patients of both genders of at least 50 years old with joint pain assessed as ≥30 mm on a visual analogical scale (VAS). Intervention: Collagen hydrolysate 1200 mg/day or placebo during 6 months. Main outcome measure: Comparison of the percentage of clinical responder between the active collagen hydrolysate group and the placebo group after 6 months of study. A responder subject was defined as a subject experiencing a clinically significant improvement (i.e. by 20% or more) in the most painful joint using the VAS score. All analyses were performed using an intent-totreat procedure. Results: At 6 months, the proportion of clinical responders to the treatment, according to VAS scores, was significantly higher in the collagen hydrolysate (CH) group 51.6%, compared to the placebo group 36.5% (p < 0.05). However, there was no significant difference between groups at 3 months (44.1% vs. 39.6%, p = 0.53). No significant difference in terms of security and tolerability was observed between the two groups. Conclusions: This study suggests that collagen hydrolysate 1200 mg/day could increase the number of clinical responders (i.e. improvement of at least 20% on the VAS) compared to placebo. More studies are needed to confirm the clinical interest of this food supplement. [less ▲]

Detailed reference viewed: 68 (26 ULg)
Full Text
Peer Reviewed
See detailMaintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.
Reginster, Jean-Yves ULg; Kaufman, J. M.; Goemaere, S. et al

in Osteoporosis International (2012), 23

In an open-label extension study, BMD increased continuously with strontium ranelate over 10 years in osteoporotic women (P < 0.01). Vertebral and nonvertebral fracture incidence was lower between 5 and ... [more ▼]

In an open-label extension study, BMD increased continuously with strontium ranelate over 10 years in osteoporotic women (P < 0.01). Vertebral and nonvertebral fracture incidence was lower between 5 and 10 years than in a matched placebo group over 5 years (P < 0.05). Strontium ranelate's antifracture efficacy appears to be maintained long term. INTRODUCTION: Strontium ranelate has proven efficacy against vertebral and nonvertebral fractures, including hip, over 5 years in postmenopausal osteoporosis. We explored long-term efficacy and safety of strontium ranelate over 10 years. METHODS: Postmenopausal osteoporotic women participating in the double-blind, placebo-controlled phase 3 studies SOTI and TROPOS to 5 years were invited to enter a 5-year open-label extension, during which they received strontium ranelate 2 g/day (n = 237, 10-year population). Bone mineral density (BMD) and fracture incidence were recorded, and FRAX(R) scores were calculated. The effect of strontium ranelate on fracture incidence was evaluated by comparison with a FRAX(R)-matched placebo group identified in the TROPOS placebo arm. RESULTS: The patients in the 10-year population had baseline characteristics comparable to those of the total SOTI/TROPOS population. Over 10 years, lumbar BMD increased continuously and significantly (P < 0.01 versus previous year) with 34.5 +/- 20.2% relative change from baseline to 10 years. The incidence of vertebral and nonvertebral fracture with strontium ranelate in the 10-year population in years 6 to 10 was comparable to the incidence between years 0 and 5, but was significantly lower than the incidence observed in the FRAX(R)-matched placebo group over 5 years (P < 0.05); relative risk reductions for vertebral and nonvertebral fractures were 35% and 38%, respectively. Strontium ranelate was safe and well tolerated over 10 years. CONCLUSIONS: Long-term treatment with strontium ranelate is associated with sustained increases in BMD over 10 years, with a good safety profile. Our results also support the maintenance of antifracture efficacy over 10 years with strontium ranelate. [less ▲]

Detailed reference viewed: 20 (8 ULg)
See detailIntérêts des traitements symptomatiques anti-arthrosiques
Bruyère, Olivier ULg

Conference (2011, December 12)

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailEvolution récente de l'incidence des fractures de hanche et de la consommation de médicaments anti-ostéoporotiques en Belgique
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Roberfroid, D. et al

in Revue du Rhumatisme (2011, December), 78(Suppl. 5), 43-44

Detailed reference viewed: 28 (7 ULg)
See detailÉtude de cas : allégations de santé dans le domaine de la santé osseuse
Bruyère, Olivier ULg

Conference (2011, November 16)

Detailed reference viewed: 10 (0 ULg)
See detailApplying Clinical Research Methodology from Pharma to Food: Osteoporosis Claims
Bruyère, Olivier ULg

Conference (2011, October 27)

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailWords, words, words
Van Oyen, Herman; Bruyère, Olivier ULg

in Archives of Public Health (2011), 69(1),

Detailed reference viewed: 21 (5 ULg)
Full Text
See detailGuidelines for the management of osteoarthritis
Bruyère, Olivier ULg

Conference (2011, March 24)

Detailed reference viewed: 26 (1 ULg)
Full Text
Peer Reviewed
See detailHospitalisation costs of hip fractures in Belgium
Hiligsmann, Mickaël ULg; Gathon, Henry-Jean ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2011, March), 22(Suppl.1), 332

Detailed reference viewed: 33 (7 ULg)
Full Text
Peer Reviewed
See detailPatient out-of-pocket contributions related to hip fracture hospital costs in Belgium
Hiligsmann, Mickaël ULg; Gathon, Henry-Jean ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2011, March), 22(Suppl.1), 333

Detailed reference viewed: 46 (23 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate increases cell viability in IL-1 beta stimulated human chondrocytes
Merville, Marie-Paule ULg; Deroyer, Céline ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2011, March), 22(Suppl.1), 53-54384

Detailed reference viewed: 41 (22 ULg)
Full Text
Peer Reviewed
See detailRisk of hip fracture in community-dwelling and institutionalized osteoporotic patients: a 3-year study
Bruyère, Olivier ULg; Hiligsmann, Mickaël ULg; Zegels, Brigitte ULg et al

in Osteoporosis International (2011, March), 22(Suppl.1), 332-333

Detailed reference viewed: 22 (7 ULg)